Rallybio Corp
RLYB.OQ- Latest Trade
- trading higher10.21USD
- Change
- 0.39
- % Change
3.97%Positive
- Day Range
- 9.70 - 10.57
- 52-Week Range
- 6.76 - 25.76
As of May 20 2022. Values delayed up to 15 minutes
- Previous Close
- 9.82
- Open
- 10.05
- Volume
- 8,281.00
- 3 Month Average Trading Volume
- 2.55
- Shares Out (Mil)
- 32.13
- Market Cap
- 346.05
- Forward P/E
- -4.94
- Dividend Yield
- -99,999.99
Key Statistics
1.8 mean rating - 5 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- -99,999.99
- Price To Book (Quarterly)
- 2.12
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -33.63
- Return On Equity (TTM)
- -32.30
2021 (millions USD)
About Rallybio Corp
Company Information
Rallybio Corporation is a clinical-stage biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering therapies that improve the lives of patients suffering from severe and rare diseases. It offers a program for the prevention of fetal and neonatal alloimmune thrombocytopenia, a rare hematological disease that impacts fetuses and newborns. It provides RLYB211, a polyclonal anti-HPA-1a antibody. Its RLYB211 is in Phase I/II clinical trial. The Company’s lead product candidate, RLYB212, is a monoclonal anti-HPA-1a antibody. It is also focused on developing therapies that address diseases of complement dysregulation, including paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG), and ophthalmic disorders. Its RLYB116 is a long-acting, subcutaneously administered inhibitor of complement factor 5 (C5) in development for the treatment of patients with PNH and gMG. It also includes RLYB114, which is a pegylated C5 inhibitor.
Address
234 CHURCH STREET, SUITE 1020NEW HAVEN, CT
06510
United States
Industry
Business Services
Executive Leadership
- Martin W. Mackay
- Chairman of the Board, Chief Executive Officer, Co-Founder
- Stephen Uden
- President, Co-Founder, Chief Operating Officer, Chief Scientific Officer
- Jeffrey M. Fryer
- Co-Founder, Chief Financial Officer, Treasurer
- Steven Ryder
- Chief Medical Officer
- Hui Liu
- Director
- Christine A. Nash
- Director
- Helen M. Boudreau
- Independent Director
- Robert Hopfner
- Independent Director
- Ronald M. Hunt
- Independent Director
- Lucian Iancovici
- Independent Director
- Kush M. Parmar
- Independent Director
- Timothy M. Shannon
- Independent Director
- Paula Soteropoulos
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,836.30 | 0.27%Negative |
| Copper | 772.55 | 0.46%Positive |
| Brent Crude Oil | 112.55 | -- |
| CBOT Soybeans | 1,705.75 | 0.90%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,901.36 | 0.01%Positive |
| Euro STOXX 50 | 3,657.03 | 0.45%Positive |
| FTSE 100 | 7,389.98 | 1.19%Positive |
| Nikkei 225 | 26,739.03 | 1.27%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes